 Drug Therapy, Combination
"Drug Therapy, Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapy with two or more separate preparations given for a combined effect.
| Descriptor ID |
D004359
|
| MeSH Number(s) |
E02.319.310
|
| Concept/Terms |
Drug Therapy, Combination- Drug Therapy, Combination
- Combination Chemotherapy
- Drug Polytherapy
- Drug Polytherapies
- Polytherapies, Drug
- Polytherapy, Drug
- Therapy, Combination Drug
- Chemotherapy, Combination
- Chemotherapies, Combination
- Combination Chemotherapies
- Combination Drug Therapy
- Combination Drug Therapies
- Drug Therapies, Combination
- Therapies, Combination Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Therapy, Combination".
Below are MeSH descriptors whose meaning is more specific than "Drug Therapy, Combination".
This graph shows the total number of publications written about "Drug Therapy, Combination" by people in this website by year, and whether "Drug Therapy, Combination" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 6 | 6 | | 1992 | 0 | 3 | 3 | | 1993 | 0 | 5 | 5 | | 1994 | 0 | 5 | 5 | | 1995 | 0 | 6 | 6 | | 1996 | 0 | 9 | 9 | | 1997 | 0 | 9 | 9 | | 1998 | 0 | 14 | 14 | | 1999 | 0 | 15 | 15 | | 2000 | 0 | 12 | 12 | | 2001 | 1 | 16 | 17 | | 2002 | 1 | 12 | 13 | | 2003 | 0 | 16 | 16 | | 2004 | 0 | 34 | 34 | | 2005 | 0 | 27 | 27 | | 2006 | 0 | 28 | 28 | | 2007 | 0 | 27 | 27 | | 2008 | 0 | 30 | 30 | | 2009 | 0 | 21 | 21 | | 2010 | 0 | 25 | 25 | | 2011 | 0 | 35 | 35 | | 2012 | 0 | 40 | 40 | | 2013 | 2 | 26 | 28 | | 2014 | 0 | 33 | 33 | | 2015 | 0 | 55 | 55 | | 2016 | 1 | 38 | 39 | | 2017 | 2 | 51 | 53 | | 2018 | 1 | 38 | 39 | | 2019 | 0 | 37 | 37 | | 2020 | 1 | 36 | 37 | | 2021 | 0 | 7 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Therapy, Combination" by people in Profiles.
-
Eikelboom JW, Bhatt DL, Fox KAA, Bosch J, Connolly SJ, Anand SS, Avezum A, Berkowitz SD, Branch KRH, Dagenais GR, Félix C, Guzik TJ, Hart RG, Maggioni AP, Muehlhofer E, Sharma M, Shestakovska O, Yusuf S. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. J Am Coll Cardiol. 2021 07 06; 78(1):14-23.
-
Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 07; 73(7):1108-1123.
-
Guzik TJ, Ramasundarahettige C, Pogosova N, Lopez-Jaramillo P, Dyal L, Berkowitz SD, Muehlhofer E, Bhatt DL, Fox KAA, Yusuf S, Eikelboom JW. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. J Am Coll Cardiol. 2021 02 09; 77(5):511-525.
-
R Arnold N, S Wan E, Hersh CP, Schwartz A, Kinney G, Young K, Hokanson J, Regan EA, P Comellas A, Fortis S. Inhaled Medication Use in Smokers With Normal Spirometry. Respir Care. 2021 Apr; 66(4):652-660.
-
Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM, Daines CL. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 02 01; 203(3):381-385.
-
Brajcich MR, Palau MA, Messer RD, Murphy ME, Marks J. Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. Pediatrics. 2021 02; 147(2).
-
Rodbard HW, Giaccari A, Cariou B, Garg S, Davies MJ, Seth K, Sawhney S. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. Diab Vasc Dis Res. 2021 Jan-Feb; 18(1):1479164121995928.
-
Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Davey VJ, Goodman A, Higgs ES, Murray DD, Murray TA, Paredes R, Parmar MKB, Phillips AN, Reilly C, Sharma S, Dewar RL, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N Engl J Med. 2021 03 11; 384(10):905-914.
-
Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol. 2021 01; 73(1):121-131.
-
Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, Leu JH, Zoka R, Hedrick JA, Rigby MR, Vercruysse F. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. N Engl J Med. 2020 11 19; 383(21):2007-2017.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|